AR076328A1 - Derivados de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 - Google Patents
Derivados de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2Info
- Publication number
- AR076328A1 AR076328A1 ARP100101287A ARP100101287A AR076328A1 AR 076328 A1 AR076328 A1 AR 076328A1 AR P100101287 A ARP100101287 A AR P100101287A AR P100101287 A ARP100101287 A AR P100101287A AR 076328 A1 AR076328 A1 AR 076328A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- dihydro
- phenyl
- onyl
- benzo
- Prior art date
Links
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 title abstract 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 22
- -1 -CsCH Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000005872 benzooxazolyl group Chemical group 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17030709P | 2009-04-17 | 2009-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076328A1 true AR076328A1 (es) | 2011-06-01 |
Family
ID=42167720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101287A AR076328A1 (es) | 2009-04-17 | 2010-04-19 | Derivados de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100267689A1 (OSRAM) |
| EP (1) | EP2419419B1 (OSRAM) |
| JP (1) | JP5675773B2 (OSRAM) |
| KR (1) | KR20120006544A (OSRAM) |
| CN (1) | CN102459227B (OSRAM) |
| AR (1) | AR076328A1 (OSRAM) |
| AU (1) | AU2010236346B2 (OSRAM) |
| BR (1) | BRPI1016189A2 (OSRAM) |
| CA (1) | CA2758934A1 (OSRAM) |
| ES (1) | ES2528625T3 (OSRAM) |
| MX (1) | MX2011010964A (OSRAM) |
| NZ (1) | NZ595432A (OSRAM) |
| TW (1) | TW201102377A (OSRAM) |
| WO (1) | WO2010121046A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018997B1 (ru) * | 2008-12-10 | 2013-12-30 | Янссен Фармацевтика Нв | Антагонисты ccr2 группы 4-азетидинил-1-гетероарилциклогексанола |
| CN102459225B (zh) * | 2009-04-16 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂 |
| ES2528625T3 (es) | 2009-04-17 | 2015-02-11 | Janssen Pharmaceutica Nv | Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2 |
| AU2010236336B2 (en) | 2009-04-17 | 2015-01-15 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 |
| TW201211027A (en) * | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| AU2011268375B2 (en) | 2010-06-17 | 2015-02-05 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| BR112014012056B1 (pt) | 2011-11-18 | 2021-12-14 | Heptares Therapeutics Limited | Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória |
| BR112014013150A2 (pt) * | 2011-12-01 | 2017-06-13 | Chemocentryx Inc | benzimidazoles e benzopirazoles substituídas como antagonistas de ccr(4) |
| US9546155B2 (en) | 2012-06-15 | 2017-01-17 | Mitsubishi Tanabe Pharma Corporation | Aromatic heterocyclic compound |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3209655B1 (en) | 2014-10-24 | 2020-07-15 | Landos Biopharma, Inc. | Lanthionine synthetase c-like 2-based therapeutics |
| EP3613435A1 (en) | 2015-01-28 | 2020-02-26 | Universite De Bordeaux | Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease |
| RS62809B1 (sr) | 2015-05-21 | 2022-02-28 | Chemocentryx Inc | Modulatori ccr2 |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| US11304952B2 (en) | 2017-09-25 | 2022-04-19 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor |
| EA202091325A1 (ru) | 2017-11-30 | 2020-08-28 | Лэндос Байофарма, Инк. | Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| EP3737367B1 (en) | 2018-01-08 | 2024-10-02 | ChemoCentryx, Inc. | Ccr2 antagonists for the treatment of cutaneous t-cell lymphoma |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110028395A (zh) * | 2019-05-29 | 2019-07-19 | 宁夏中星显示材料有限公司 | 一种4-(4-羟基苯基)环己酮的制备方法 |
| US11117881B2 (en) | 2019-12-20 | 2021-09-14 | Landos Biopharma, Inc. | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998285A4 (en) | 1997-06-18 | 2003-01-08 | Merck & Co Inc | ANTAGONISTS OF THE ALPHA 1a ADRENERIC RECEPTOR |
| US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| AU4796700A (en) * | 1999-05-13 | 2000-12-05 | Dupont Pharmaceuticals Research Laboratories, Inc. | Ureido-substituted cyclic amine derivatives and their use as drug |
| WO2001010439A1 (en) | 1999-08-04 | 2001-02-15 | Teijin Limited | Cyclic amine ccr3 antagonists |
| MXPA02004555A (es) | 1999-11-08 | 2004-09-10 | Wyeth Corp | Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central. |
| US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| DE50207201D1 (de) * | 2001-03-26 | 2006-07-27 | Bayer Materialscience Ag | Polycarbonat mit ausgeprägtem scherentzähungsverhalten |
| GEP20115290B (en) * | 2002-11-27 | 2011-09-26 | Incyte Corp | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| UA87449C2 (ru) * | 2002-11-27 | 2009-07-27 | Инсайт Корпорейшн | Производные 3-аминопиролидина как модуляторы рецепторов хемокина |
| WO2005060665A2 (en) | 2003-12-18 | 2005-07-07 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| EP1802602A1 (en) * | 2004-09-28 | 2007-07-04 | Janssen Pharmaceutica N.V. | Substituted dipiperdine ccr2 antagonists |
| PA8653301A1 (es) * | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
| GB0513747D0 (en) | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| US8569282B2 (en) * | 2007-12-11 | 2013-10-29 | Cytopathfinder, Inc. | Carboxamide compounds and their use |
| EA018997B1 (ru) * | 2008-12-10 | 2013-12-30 | Янссен Фармацевтика Нв | Антагонисты ccr2 группы 4-азетидинил-1-гетероарилциклогексанола |
| CN102459225B (zh) * | 2009-04-16 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂 |
| ES2528625T3 (es) | 2009-04-17 | 2015-02-11 | Janssen Pharmaceutica Nv | Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2 |
| AU2010236336B2 (en) * | 2009-04-17 | 2015-01-15 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2 |
-
2010
- 2010-04-15 ES ES10714804.1T patent/ES2528625T3/es active Active
- 2010-04-15 KR KR1020117026846A patent/KR20120006544A/ko not_active Withdrawn
- 2010-04-15 EP EP10714804.1A patent/EP2419419B1/en active Active
- 2010-04-15 MX MX2011010964A patent/MX2011010964A/es active IP Right Grant
- 2010-04-15 WO PCT/US2010/031265 patent/WO2010121046A1/en not_active Ceased
- 2010-04-15 JP JP2012506232A patent/JP5675773B2/ja not_active Expired - Fee Related
- 2010-04-15 NZ NZ595432A patent/NZ595432A/en not_active IP Right Cessation
- 2010-04-15 CN CN201080027641.6A patent/CN102459227B/zh not_active Expired - Fee Related
- 2010-04-15 CA CA2758934A patent/CA2758934A1/en not_active Abandoned
- 2010-04-15 AU AU2010236346A patent/AU2010236346B2/en not_active Ceased
- 2010-04-15 US US12/761,080 patent/US20100267689A1/en not_active Abandoned
- 2010-04-15 BR BRPI1016189A patent/BRPI1016189A2/pt not_active Application Discontinuation
- 2010-04-16 TW TW099111898A patent/TW201102377A/zh unknown
- 2010-04-19 AR ARP100101287A patent/AR076328A1/es unknown
-
2011
- 2011-10-25 US US13/280,690 patent/US8513229B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120006544A (ko) | 2012-01-18 |
| US20120040960A1 (en) | 2012-02-16 |
| MX2011010964A (es) | 2011-11-02 |
| TW201102377A (en) | 2011-01-16 |
| JP2012524111A (ja) | 2012-10-11 |
| AU2010236346B2 (en) | 2015-01-22 |
| CA2758934A1 (en) | 2010-10-21 |
| NZ595432A (en) | 2013-12-20 |
| ES2528625T3 (es) | 2015-02-11 |
| JP5675773B2 (ja) | 2015-02-25 |
| BRPI1016189A2 (pt) | 2016-04-19 |
| CN102459227B (zh) | 2014-08-20 |
| EP2419419A1 (en) | 2012-02-22 |
| US20100267689A1 (en) | 2010-10-21 |
| US8513229B2 (en) | 2013-08-20 |
| AU2010236346A1 (en) | 2011-11-03 |
| EP2419419B1 (en) | 2014-12-03 |
| WO2010121046A1 (en) | 2010-10-21 |
| CN102459227A (zh) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076328A1 (es) | Derivados de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 | |
| AR074583A1 (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
| CL2008002330A1 (es) | Compuestos derivados de alcoholes de 1-fenil-2-piridinilalquilo, inhibidores de la fosfodiesterasa 4 (pde4); proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; y su uso para preparar medicamentos utiles en la prevencion o tratamiento de asma, bronquitis cronica y epoc. | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| AR076310A1 (es) | 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2,composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes,obesidad y otras enfermedades. | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR055916A1 (es) | Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica | |
| AR069524A1 (es) | Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento | |
| UY32759A (es) | Inhibidores del virus de la hepatitis c | |
| BRPI1013821A8 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| RU2008142834A (ru) | Модуляция церамидкиназы | |
| AR080328A1 (es) | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| AR076329A1 (es) | 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes, obesidad y otras enfermedades. | |
| ES2587304T3 (es) | Derivados de diaminopirimidina y procedimientos para la preparación de los mismos | |
| MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
| BR112015015275A8 (pt) | composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso | |
| AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
| AR077367A1 (es) | 2- carboxamida -cicloamino-ureas sustituidas | |
| CL2007003042A1 (es) | Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |